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ABSTRACT 
 
Background: Both medial temporal cortical dysfunction and perturbed glutamatergic 
neurotransmission are regarded as fundamental pathophysiological features of psychosis. However, 
while animal models of psychosis suggest that these two abnormalities are inter-related, their 
relationship in humans has yet to be investigated.  
 
Methods: We used a combination of functional MRI (fMRI) and MR spectroscopy (MRS) to 
investigate the relationship between medial temporal activation during an episodic memory task and 
local glutamate levels in 22 individuals with an At Risk Mental State for psychosis and 14 healthy 
volunteers.   
  
Results: We observed a significant between group difference in the coupling of medial temporal 
activation with local glutamate levels. In controls, medial temporal activation during episodic 
encoding was positively associated with medial temporal glutamate. However, in the clinical 
population, medial temporal activation was reduced and the relationship with glutamate was absent.  
 
Conclusions: In individuals at high risk of psychosis medial temporal dysfunction appeared related 
to a loss of the normal relationship with local glutamate levels. This study provides the first 
evidence that links medial temporal dysfunction with the central glutamate system in humans, and 
is consistent with evidence that drugs that modulate glutamatergic transmission may be useful in the 
treatment of psychosis. 
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INTRODUCTION 
Psychotic disorders have frequently been associated with alterations in the structure and function of 
the medial temporal cortex (1, 2), and abnormalities in this region are thought to underlie the 
memory impairments that are evident in patients with psychosis at the behavioural level (3). An 
independent body of evidence indicates that perturbed glutamatergic neurotransmission is a key 
neurochemical feature of psychosis. N-methyl-D-aspartate glutamate (NMDA) receptor antagonists, 
such as ketamine, induce acute psychotic symptoms and impair memory performance (4), and 
psychotic disorders are associated with increased glutamine in the anterior cingulate cortex and 
thalamus (5), and a reduction in activated hippocampal NMDA receptor density (6) and NMDA 
receptor subunit mRNA (7). Animal models of psychosis and circuit analyses suggest that 
glutamatergic and medial temporal abnormalities are inter-related, with medial temporal cortex 
considered critical for the memory impairments observed after NMDA antagonists administration 
and in psychosis (8). The onset of psychotic disorders is preceded by a prodromal phase 
characterised by attenuated psychotic symptoms and a decline in global function. Recent studies in 
this phase of the disorder suggest that both hippocampal dysfunction and perturbed glutamate 
function are evident before the clinical expression of illness (9, 10), and that its onset is associated 
with progressive volumetric changes in the medial temporal cortex (11).  
We examined the relationship between medial temporal function and central glutamate levels in 
people presenting with prodromal symptoms of psychosis. We first predicted, on the basis of 
previous studies (10, 12), that they would show altered medial temporal activation when performing 
a memory task, and alterations in regional glutamate levels. We then tested our main hypothesis, 
that the degree of medial temporal dysfunction would be related to the alteration in regional 
glutamate levels. 
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METHODS AND MATERIALS 
We used a combination of functional magnetic resonance imaging (fMRI) and proton magnetic 
resonance spectroscopy (1H-MRS) in the same individuals. The study was approved by the Joint 
South London and Maudsley and The Istitute of Psychiatry NHS research ethics committee, and all 
participants gave written informed consent to participate after a complete description of the study.  
Subjects 
Twenty-two subjects with an At Risk Mental State (ARMS) for psychosis (13), and a matching 
group of sixteen healthy volunteers took part in the study. However two of the control subjects were 
subsequently excluded, due to the poor quality of their MRS data in the hippocampal region. 
Participants were aged 18 to 30 years and excluded if their IQ was below 70, if there was a history 
of a neurological disorder or if they met DSM-IV criteria for a substance abuse disorder. The 
clinical population was recruited from Outreach and Support in South London (OASIS), a clinical 
service for people at high risk of developing a psychotic disorder, where subjects were assessed by 
two expert clinicians using the Comprehensive Assessment of At Risk Mental States (CAARMS, 
(13)) and diagnosis confirmed at a consensus clinical meeting. All subjects were antipsychotic 
naïve at the time of scanning, 3 subjects were receiving antidepressant treatment. The ARMS 
subjects were matched based on age, sex and IQ to a sample of healthy controls selected from the 
same sociodemographic area and recruited via advertisement (supplementary Table S1). All 
participants were right handed, as evaluated using the Lateral Preferences Inventory (14) and native 
English speakers. 
Clinical Measures 
Current symptoms were assessed in all the participants at the time of scanning using the CAARMS  
and the Positive and Negative Symptom Scale (PANSS, (15)). Premorbid IQ was measured with the 
Wide Range Achievement Test-Revised (WRAT-R, (16)). 
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Imaging 
1H-MRS was used to measure glutamate levels in the medial temporal cortex, anterior cingulate 
cortex, and thalamus (10). During the functional MRI session, subjects performed a verbal episodic 
memory paradigm that normally engages the medial temporal cortex (12) (supplementary Tables S3 
and S4). During an encoding condition they read words aloud and were asked to remember them. In 
a recognition condition, they were presented with a subset of these words, mixed with novel, 
unstudied words, and asked whether they remembered them. To examine the correlation between 
BOLD response during the task and glutamatergic function, beta values were extracted from a 
region showing a between group difference in activation, and Pearson’s correlation was performed 
in SPSS version 16.0 (SPSS inc. Chicago, Illinois, USA) to evaluate the association with local 
glutamate levels. Cook’s distance test and leverage plot were used to assess the effect of potential 
outliers and influential cases (details of imaging procedures and data analysis in online 
supplementary Methods). 
 
RESULTS 
Consistent with previous studies (12), during verbal encoding the ARMS group showed reduced 
activation relative to controls in the left parahippocampal gyrus (PHG; p=0.047 FWE; fig 1), where 
the degree of activation in the ARMS group was directly correlated with task performance (the 
number of words correctly recalled during the subsequent recognition condition; r=0.497, df=20, 
p=0.019). In controls, activation in this cluster during encoding was positively correlated with left 
medial temporal glutamate levels (r=0.592, df=12, p=0.026) (Fig 1), whereas there was a negative 
correlation in the ARMS subjects (r=-0.447, df=20, p=0.037). When Cook’s distance test and 
leverage plot were used, the result in the ARMS group appeared driven by one case. When this 
subject was excluded the correlation in the ARMS group was no longer significant (r=-0.318, 
df=19, p=0.16) (fig 1). To assess the potential effects of antidepressant treatment on the data, we 
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performed a sensitivity analysis, repeating the correlation after the exclusion of the three medicated 
ARMS subjects. This did not alter the results:  again, there was no significant relationship between 
activation in the left parahippocampal cluster and medial temporal glutamate (r=-0.414, df=14, 
p=0.088). Fisher r to z transformation was used to formally assess the difference in the correlations 
within each group, and showed a significant difference between the respective correlation 
coefficients (Z=2.64; p<0.01). 
  
There were no significant group differences in regional glutamate levels (although there was a trend 
[p=0.079] for a reduction in the thalamus in the ARMS group; details in Table S5 of online 
supplementary material). There were no group differences in medial temporal activation during the 
recognition (as opposed to the encoding) condition. We therefore did not assess the relationship 
between glutamate levels and medial temporal activation during the recognition phase of the task. 
 
 
***FIGURE 1 ABOUT HERE*** 
Fig 1: Left parahippocampal (PHG) region (x=-18 y=-30 z=-20) where ARMS subjects showed less 
activation (in arbitrary units) than controls during encoding (p=0.047 FWE). In this region, 
activation in controls was positively correlated with left medial temporal glutamate levels, but there 
was no correlation in the ARMS group. 
 
 
DISCUSSION 
These results suggest that medial temporal dysfunction in people with prodromal symptoms of 
psychosis is related to a loss of the normal relationship between function in this region and local 
glutamate levels. While both medial temporal dysfunction and altered glutamate levels have each 
been described separately in relation to psychosis in humans (2, 5), this is the first time a link 
                                                                                                                              Isabel Valli I et 
al. 
7 
between them has been demonstrated in the same subjects. A direct relationship between them 
provides support to contemporary animal models of psychosis, which propose that medial temporal 
dysfunction is associated with a disturbance of glutamate neurotransmission (8).  
 
NMDA receptor antagonists can induce neuronal damage in the limbic cortex of rodents. This effect 
is prevented by pretreatment with gamma-aminobutyric acid (GABA) receptor agonists, suggesting 
that it involves blockade of excitatory glutamate receptors on GABAergic inhibitory interneurons 
(17). An effect on GABAergic interneurons may also underlie the emergence of psychotic 
symptoms observed following NMDA receptor blockade in humans (18), and a similar mechanism 
has been hypothesised for the glutamate model of psychosis (18). The specificity of our findings to 
the encoding, as opposed to the recognition phase of the memory task is consistent with evidence 
that infusion of NMDA receptor antagonists in the limbic cortex of rodents impairs memory 
encoding, but not recognition (19). A similar impairment has been observed in humans, where 
ketamine administration induces robust episodic memory impairments affecting mainly early 
consolidation processes (20) during the encoding of information (21) . This may reflect the role of 
hippocampal NMDA receptors in the induction of the activity-dependent synaptic plasticity that 
underlies memory (22). 
 
While our results suggest that medial temporal dysfunction in people at high risk of psychosis 
is  related  to  regional  glutamate  levels,  they  cannot  reveal  the  direction  of  causality,  nor 
whether the MRS measure is related to activity in medial temporal pyramidal neurons, in the 
terminals of afferent projections from other regions, or abnormalities at a receptor level. 
A  further  caveat  is  that  it  is  difficult  to  conclusively  discriminate  between  the  signals 
corresponding to glutamate and glutamine with the MRS method we used. Due to the partial 
overlap of glutamate and glutamine resonances at 3T, glutamate  levels  in  the present study 
may  thus  include  a  contribution  from  glutamine.  Simulation  studies  suggest  that  glutamine 
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may  account  for  10‐15%  of  the  glutamate  concentration  at  3T (23). The group sizes in the 
present study were modest and unequal, and replication of the findings in a larger sample is 
indicated. However, although we cannot exclude the effect of sample size on power, this is unlikely 
to have affected the main findings of the present study. The positive correlation observed between 
parahippocampal activation and hippocampal glutamate levels was present in the control group with 
a smaller sample size, but absent in the ARMS group with a larger sample. In conclusion, the 
findings are consistent with evidence that drugs which modulate glutamate transmission may be 
useful in patients with psychosis (24). Moreover, because the changes we observed predated the 
clinical expression of psychosis, they suggest that glutamatergic drugs may be able to influence the 
risk of developing the first episode of psychosis. 
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